AbbVie Inc.

AbbVie’s 2025 10-K presents a curious case, with Altman’s Z″ — a 1968 bankruptcy-distress index — registering a concerning 0.27. This score falls squarely in the “distress” zone (below 1.10), suggesting a non-trivial risk of financial failure. This finding emerges despite the MD&A’s opening with a standard discussion and analysis of financial condition, which generally sets the stage for reviewing the company’s operational results without immediate alarm. The starkness of the Z″ score immediately flags the filing for deeper scrutiny.

Beneish’s 1999 eight-ratio earnings-manipulation detector, however, paints a different picture, with a score of -2.8604. This is well below the -1.78 threshold, indicating a lower probability of earnings manipulation. The Piotroski F-Score, a 9-point fundamental strength scan, and the Fog Index, a readability score, are both noted as “not available” in the provided data. The divergence between a strong Beneish, suggesting clean reporting, and a weak Altman, indicating financial fragility, suggests a company whose underlying financial structure warrants scrutiny even if its accounting choices appear less aggressive.

The MD&A’s procedural note is also worth observing. It explicitly states that discussions of 2023 items and year-to-year comparisons between 2024 and 2023 that are not included in this Form 10-K are instead located in the prior year’s filing. This approach fragments the historical financial narrative, requiring readers to cross-reference multiple annual reports to construct a complete three-year trend analysis. Typically, a single 10-K presents this historical context cohesively, making this fragmentation an unusual structural choice for a comprehensive review.

These forensic indicators offer a quantitative lens into AbbVie’s financial reporting and solvency profile. They do not, however, provide insight into the future success of the company’s drug pipeline, the competitive landscape for its key products, or the impact of patent expirations — all critical drivers for a biopharmaceutical entity. The filing’s structure, particularly regarding historical comparisons, further necessitates diligent review beyond the current document for a complete picture. Read the 10-K. Decide for yourself.